Early and late manifestations of neuropathy due to HSPB1 mutation in the Jewish Iranian population.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
06 2021
Historique:
revised: 04 03 2021
received: 11 11 2020
accepted: 16 03 2021
pubmed: 12 5 2021
medline: 13 1 2022
entrez: 11 5 2021
Statut: ppublish

Résumé

Mutations in the HSPB1 gene are associated with a distal hereditary motor neuropathy type 2 (dHMN2) or Charcot-Marie-Tooth disease type 2F (CMT2F), usually with autosomal dominant inheritance. This study aimed to describe the phenotype of the HSPB1 c.407G>T (p.Arg136Leu) mutation at early and late stages of the disease course. We identified this mutation (previously reported in patients from Italy) in a heterozygous state, among 14 individuals from eight families of Jewish Iranian descent. The clinical, electrophysiological and ultrasonographic features were evaluated during early (less than 5 years, N = 9) or late disease course (N = 5). The majority of subjects were males with a mean age at onset of 43.4 years (range 21-67). Common initial symptoms were gait imbalance, distal (often asymmetric) lower limb weakness and feet numbness. Neurological examination in early disease course showed distal lower extremity weakness in nearly all cases, and absent Achilles tendon reflex in about half. A minority had distal loss of pain, vibration or position sensation. These findings were more prevalent in late disease stage. Electrodiagnostic studies demonstrated a length-dependent axonal motor neuropathy, with typical preferential involvement of the tibial nerve. Muscle ultrasound showed a corresponding length-dependent increase of homogeneous echo-intensity, most noticeably in the gastrocnemius. One patient had a dual diagnosis of CMT2F and CMT2W. The HSPB1 c.407G>G (p.Arg136Leu) mutation causes an adult-onset, predominantly motor, axonal neuropathy in individuals of Jewish Iranian descent. Variable manifestations are noticed, and sensory involvement is more prominent in prolonged disease duration.

Identifiants

pubmed: 33973728
doi: 10.1002/acn3.51362
pmc: PMC8164855
doi:

Substances chimiques

HSPB1 protein, human 0
Heat-Shock Proteins 0
Molecular Chaperones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1260-1268

Informations de copyright

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Hum Mutat. 2017 May;38(5):556-568
pubmed: 28144995
J Peripher Nerv Syst. 2011 Dec;16(4):287-94
pubmed: 22176143
J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):958-62
pubmed: 20660910
Neurobiol Dis. 2019 Oct;130:104505
pubmed: 31212070
J Neurol Sci. 1984 Apr;64(1):33-43
pubmed: 6737002
J Peripher Nerv Syst. 2018 Mar;23(1):40-48
pubmed: 29381233
Nat Genet. 2001 Sep;29(1):83-7
pubmed: 11528398
Clin Neurol Neurosurg. 2016 May;144:67-71
pubmed: 26989944
Exp Mol Med. 2008 Jun 30;40(3):304-12
pubmed: 18587268
Skeletal Radiol. 2012 May;41(5):515-24
pubmed: 21611841
Neuromuscul Disord. 2017 Jan;27(1):50-56
pubmed: 27816334
Muscle Nerve. 2016 Sep;54(3):371-7
pubmed: 27238640
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32093037
Cell Stress Chaperones. 2020 Jul;25(4):655-665
pubmed: 32301006
Cell Stress Chaperones. 2020 Jul;25(4):679-699
pubmed: 32323160
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934
Neurology. 2008 Nov 18;71(21):1660-8
pubmed: 18832141
Front Mol Biosci. 2016 Dec 14;3:81
pubmed: 28018906
Neurol Res. 2011 Dec;33(10):1016-24
pubmed: 22196753
Neurol Sci. 2015 Jun;36(6):1003-6
pubmed: 25547330
Hum Mutat. 2018 Mar;39(3):415-432
pubmed: 29235198
J Peripher Nerv Syst. 2020 Sep;25(3):223-229
pubmed: 32639100
Arch Neurol. 2005 Aug;62(8):1201-7
pubmed: 16087758
Nat Genet. 2004 Jun;36(6):602-6
pubmed: 15122254

Auteurs

Lior Greenbaum (L)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Merav Ben-David (M)

Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Vera Nikitin (V)

Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Orna Gera (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Ortal Barel (O)

The Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.
Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.

Adi Hersalis-Eldar (A)

Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Jana Shamash (J)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Noam Shimshoviz (N)

The Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.
Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.

Haike Reznik-Wolf (H)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Mordechai Shohat (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.
Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.

Dan Dominissini (D)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.
Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.

Elon Pras (E)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amir Dori (A)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH